A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia

Trial Profile

A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Romiplostim (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2017 Planned End Date changed from 1 Apr 2016 to 14 Jul 2018.
    • 09 Apr 2017 Status changed from suspended to discontinued.
    • 22 Jul 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top